BioMarin Pharmaceuticals BMRN Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's interest expense?
- BioMarin Pharmaceuticals (BMRN) reported interest expense of $14.96M in Q1 2026.
- How has BioMarin Pharmaceuticals's interest expense changed year-over-year?
- BioMarin Pharmaceuticals's interest expense increased by 422.5% year-over-year, from $2.86M to $14.96M.
- What is the long-term trend for BioMarin Pharmaceuticals's interest expense?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's interest expense has grown at a -8.2% compound annual growth rate (CAGR), from $15.34M to $10.9M.
- What does interest expense mean?
- The cost of borrowing money.
- How do you interpret interest expense?
- Lower interest expense is generally preferred as it indicates lower debt levels or more favorable financing terms.
- How does interest expense compare across companies?
- Benchmark against peers based on debt-to-equity ratios and credit ratings.